Insulin Aspart Sanofi (Insulin Aspart)

Insulin Aspart is a rapid‑acting insulin analog used to control blood glucose in diabetes mellitus.

• Type 1 diabetes mellitus: improves post‑prandial glucose control and reduces hyperglycaemic excursions.
• Type 2 diabetes mellitus: assists in achieving glycaemic targets when combined with oral agents or basal insulin.

• Insulin Aspart binds to the insulin receptor on cell membranes, activating the receptor’s tyrosine kinase activity. This triggers intracellular signaling that promotes translocation of GLUT‑4 transporters to the cell surface, enhancing glucose uptake in muscle and adipose tissue and suppressing hepatic glucose production. Its modified amino‑acid sequence confers a rapid onset of action after subcutaneous injection.

Insulin Aspart may cause a range of adverse reactions.

Common Side Effects

• Hypoglycaemia: low blood glucose levels, especially if meals are missed.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Lipodystrophy: localized changes in subcutaneous fat with repeated injections.
• Weight gain: modest increase associated with improved glycaemic control.

Serious or Rare Side Effects

• Severe hypoglycaemia leading to loss of consciousness or seizures.
• Anaphylactic reaction: hives, difficulty breathing, or swelling of the face.
• Hypersensitivity with angio‑edema or severe skin rash.
• Development of insulin antibodies that may alter drug efficacy.
• Edema: fluid retention, particularly in the lower extremities.

When using Insulin Aspart, several safety considerations are recommended.

• Dose adjustment: monitor blood glucose frequently and modify dose when meals, activity, or health status change.
• Renal impairment: reduced clearance may require lower doses to avoid hypoglycaemia.
• Hepatic impairment: use with caution as liver disease can affect glucose metabolism.
• Pregnancy: limited data; prescribe only if potential benefit justifies potential risk to the fetus.
• Hypoglycaemia risk: educate patients on recognising and treating low blood glucose promptly.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin Aspart can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Beta‑blockers: may mask symptoms of hypoglycaemia, delaying treatment.
• Monoamine oxidase inhibitors (MAOIs): can potentiate insulin’s glucose‑lowering effect.
• Concurrent use of other insulins or secretagogues: increases risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely)

• ACE inhibitors: may enhance insulin sensitivity, requiring dose review.
• Thiazide diuretics: can raise blood glucose levels, potentially reducing insulin effectiveness.